Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme

Stefan Schreiber; David T. Rubin; Siew C. Ng; Laurent Peyrin‐Biroulet; Silvio Danese; Irene Modesto; Xiang Guo; Chinyu Su; Kenneth Kwok; Hyejin Jo; Yan Chen; Arne Yndestad; Walter Reinisch; Marla C. Dubinsky

doi:10.1093/ecco-jcc/jjad104

July 4, 2023Journal of Crohn s and ColitisOpen Access

Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme

View Full Paper

Ask AI

Bookmark

Share

Key Points

To assess incidence rates of major adverse cardiovascular events stratified by baseline cardiovascular risk in patients with ulcerative colitis receiving tofacitinib.
Analyzed data from N=1157 patients with ulcerative colitis across the OCTAVE clinical programme (NCT00787202, NCT01465763, NCT01458951, NCT01458574, NCT01470612), representing 2814.4 patient-years of exposure and up to 7.8 years of tofacitinib treatment.
Categorized patients at baseline by history of atherosclerotic cardiovascular disease (ASCVD) or calculated 10-year ASCVD risk (low, borderline, intermediate, high).
Overall, 8 of 1157 patients (0.7%) experienced major adverse cardiovascular events (MACE), with an incidence rate of 0.95 (95% CI, 0.02–5.27) per 100 patient-years among those with prior ASCVD.
Among patients without prior ASCVD, MACE incidence rates per 100 patient-years were 1.81 (95% CI, 0.05–10.07) for high, 1.54 (95% CI, 0.42–3.95) for intermediate, 0.00 (95% CI, 0.00–2.85) for borderline, and 0.09 (95% CI, 0.01–0.32) for low baseline 10-year risk.
Five of seven patients who developed MACE without prior ASCVD exhibited higher 10-year ASCVD risk scores prior to the event compared with baseline, primarily driven by advancing age.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Study analysis reveals major adverse cardiovascular events concentrate in ulcerative colitis patients with higher baseline risk, highlighting the importance of cardiovascular screening.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Schreiber et al. (2023) studied this question.

synapsesocial.com/papers/6a0070bfef8139f8ff779418 https://doi.org/10.1093/ecco-jcc/jjad104

View Full Paper

Ask AI

Bookmark

Share

Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading